Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Report Date: June 5, 2025
Event Date: June 5, 2025 (Filing of Certificate of Amendment); June 10, 2025 (Effective Date of Reverse Stock Split)
The Company filed a Certificate of Amendment with the Delaware Secretary of State to effect a reverse stock split of its common stock.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data.
- Revenue, Profit, Cash Flow, Margins: Not provided in this filing.
- Debt and Liquidity: Not provided in this filing.
- Stock Structure Change: 1-for-6 reverse stock split.
Material Changes
The primary material change is the modification of the rights of security holders regarding the Company's Common Stock:
- Split Ratio: 1-for-6 (every 6 shares combined into 1 share).
- Effective Time: 12:01 a.m. Eastern Time on June 10, 2025.
- Trading Symbol: Remains "BBLG" on the Nasdaq Capital Market.
- Warrants: Symbol "BBLGW" remains unchanged; exercise prices and share counts will be proportionately adjusted.
- Fractional Shares: Will be rounded up to the nearest whole share.
- Authorized Shares: Total number of authorized shares remains unchanged.
- New CUSIP: 098070600 for Common Stock.
Guidance, Outlook, and Risks
Management Commentary: The Company expects trading to commence on a post-split basis on June 10, 2025. The split does not change the par value, voting rights, or other terms of the Common Stock.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ due to risks associated with being an undercapitalized developing company. Investors are directed to the "Risk Factors" and "Management's Discussion and Analysis" in the Annual Report on Form 10-K for the year ended December 31, 2024.
Investor Verification Checklist
- Verify the new CUSIP number (098070600) for post-split trading.
- Confirm the adjustment of warrant exercise prices and share counts in brokerage accounts.
- Check for the rounding up of fractional shares in personal holdings.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal terms.
- Monitor the press release (Exhibit 99.1) for any additional details on the implementation.